Drug discovery

#AI / data analytics / healthtech / informatics #CNS #Collaboration #Drug discovery

Insilico Medicine and CMS announce CNS disease collaboration 

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings has announced an AI‑empowered drug discovery collaboration.   The collaboration is targeting a mass-market indication in central nervous system (CNS) with an innovative mechanism of action (MoA) identified by PandaOmics. According to the collaboration agreement, the two parties will jointly advance the co-development… Read More

#News

Cell and gene therapy
#Drug discovery #Gene therapy #Metabolic diseases #Preclinical development

Study proves preclinical efficacy of gene therapy for metabolic disorder 

Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has revealed preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy approach to treat metabolic disorder methylmalonic acidemia (MMA).  The findings, published in the Journal of Hepatology, show that a single systemic administration of a lentiviral vector… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Webinar

Watch now: Real-time chemistry coordination for modern drug discovery

In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More

#News

#Cambridge Omics Centre #Drug discovery #Metabolomics #Multiomics #Novogene Europe

Novogene Europe launches untargeted metabolomics service

Multiomics research services partner Novogene Europe has launched its Untargeted Metabolomics Service through its Cambridge Omics Centre. This new capability will help researchers across the UK and Europe to connect molecular data with biological function by adding metabolite-level insight to genomics, transcriptomics, microbiome and broader life science studies. Untargeted Metabolomics… Read More

#News

Neural networks
#AI / data analytics / healthtech / informatics #Cancer Research Horizons #Drug discovery #Francis Crick Institute #Medicines Discovery Catapult (MDC)

National programme to support data-driven health start-ups 

Applications have opened for a national accelerator programme supporting data-driven health innovation.  KQ Labs, led by the Francis Crick Institute and Medicines Discovery Catapult (MDC), is an annual five-month programme for early-stage companies building science-backed, scalable solutions in AI-driven drug discovery, digital health, and precision medicine. … Read More

#News

Neuroscience Parkinson's disease
#Biology #Drug discovery #Neuroscience #Parkinson's

Parkinson’s disease and CDNF: Turning a neurotrophic factor into a viable therapy 

Henri Huttunen CSO of Herantis Pharma discusses the challenges of using neurotrophic factors as a treatment for Parkinson’s disease.   Many successful drugs originate from molecules that already exist within the human body. Hormones, neurotransmitters and other endogenous molecules perform essential biological functions, making them attractive starting points for therapeutic development. If a… Read More

#Exclusive Content

Breast cancer research
#Breast cancer #Clinical development #Drug discovery #Partnership #Preclinical development

Astex partners with Genentech on breast cancer treatments 

Pharmaceutical company Astex has entered an exclusive worldwide research agreement with Genentech to identify treatments for breast cancer.  The partnership will aim to find small molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer, leveraging Astex’s fragment-based drug discovery programme.  Under the terms of… Read More

#News

GBP pound sterling funding
#Antibodies #Drug discovery #Investment

Alchemab receives £25 million from British Business Bank 

Biotech Alchemab Therapeutics has extended its series A financing with a £25 million ($34 million) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date.   The company says the funding will enable it to build its clinical pipeline and grow its antibody dataset to more… Read More

#News

#Drug discovery #Drug Discovery Innovators & Investors #Events #Innovation #Innovators & Investors #Investment

Introducing the Drug Discovery Innovators & Investors Event Series

We’re excited to announce the launch of Drug Discovery Innovators & Investors (DDII) – a new event series from Drug Discovery World. The three-part global event series focuses on technology, innovation, and investment in early-stage drug discovery. Bringing together senior executives, R&D leaders, lab managers, and decision-makers from pharma and… Read More

#Editor's Choice #News

#Chemistry #Drug discovery #Laboratory

UK minister opens £6.1m lab for ‘groundbreaking discoveries’ 

UK science minister Lord Vallance has opened a new £6.1 million ($8.2 million) lab, set to be used for drug discovery.  The Aston Institute for Membrane Excellence (AIME), funded by Aston University, is a globally unique, cross-disciplinary institute focussed on investigating novel membranes for use in applications as… Read More

#News

Magic mushrooms
#Clinical trial #Drug discovery #Psilocybin #Weight loss

‘Magic mushroom’ compounds could help treat anorexia

Compounds derived from ‘magic mushrooms’ could be a potential treatment for anorexia nervosa, a study says.  A small pilot trial from the Centre for Psychedelic Research at Imperial College London indicates that psilocybin – the active ingredient in psychedelic ‘magic mushrooms’ – may have potential as a treatment for… Read More

#News

Neuroscience
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

Webinar: Opportunities in neuroscience drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

Neuroscience
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

DDW Neuroscience webinar: Opportunities for drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of new therapies… Read More

Webinar date:
Sponsored by BioIVT
#Webinars

Big Ben and Houses of Parliament
#BioIndustry Association #Drug discovery #UK #UK government

UK life sciences industry calls on Government to boost innovation

With the upcoming change of Prime Minister, the UK’s life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.  At a UK BioIndustry Association (BIA) industry roundtable with Dr Zubir Ahmed MP, the life sciences and biotech industry emphasised… Read More

#Business & Investment #News